PMID- 37810956
OWN - NLM
STAT- MEDLINE
DCOM- 20231101
LR  - 20231101
IS  - 1178-1998 (Electronic)
IS  - 1176-9092 (Print)
IS  - 1176-9092 (Linking)
VI  - 18
DP  - 2023
TI  - Rapamycin Responds to Alzheimer's Disease: A Potential Translational Therapy.
PG  - 1629-1639
LID - 10.2147/CIA.S429440 [doi]
AB  - Alzheimer's disease (AD) is a sporadic or familial neurodegenerative disease of 
      insidious onset with progressive cognitive decline. Although numerous studies 
      have been conducted or are underway on AD, there are still no effective drugs to 
      reverse the pathological features and clinical manifestations of AD. Rapamycin is 
      a macrolide antibiotic produced by Streptomyces hygroscopicus. As a classical 
      mechanistic target of rapamycin (mTOR) inhibitor, rapamycin has been shown to be 
      beneficial in a variety of AD mouse and cells models, both before the onset of 
      disease symptoms and the early stage of disease. Although many basic studies have 
      demonstrated the therapeutic effects of rapamycin in AD, many questions and 
      controversies remain. This may be due to the variability of experimental models, 
      different modes of administration, dose, timing, frequency, and the availability 
      of drug-targeting vehicles. Rapamycin may delay the development of AD by reducing 
      beta-amyloid (Abeta) deposition, inhibiting tau protein hyperphosphorylation, 
      maintaining brain function in APOE epsilon4 gene carriers, clearing chronic 
      inflammation, and improving cognitive dysfunction. It is thus expected to be one 
      of the candidates for the treatment of Alzheimer's disease.
CI  - (c) 2023 Hou et al.
FAU - Hou, Si-Jia
AU  - Hou SJ
AD  - Department of Neurology, Headache Center, The First Hospital of Shanxi Medical 
      University, Taiyuan, Shanxi Province, 030001, People's Republic of China.
FAU - Zhang, Sheng-Xiao
AU  - Zhang SX
AD  - Department of Rheumatology, The Second Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi Province, 030009, People's Republic of China.
FAU - Li, Yang
AU  - Li Y
AUID- ORCID: 0000-0002-1336-9566
AD  - Department of Neurology, Headache Center, The First Hospital of Shanxi Medical 
      University, Taiyuan, Shanxi Province, 030001, People's Republic of China.
FAU - Xu, Sui-Yi
AU  - Xu SY
AUID- ORCID: 0000-0002-8908-011X
AD  - Department of Neurology, Headache Center, The First Hospital of Shanxi Medical 
      University, Taiyuan, Shanxi Province, 030001, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231002
PL  - New Zealand
TA  - Clin Interv Aging
JT  - Clinical interventions in aging
JID - 101273480
RN  - W36ZG6FT64 (Sirolimus)
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (tau Proteins)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Alzheimer Disease/genetics
MH  - Sirolimus/pharmacology/therapeutic use
MH  - *Neurodegenerative Diseases
MH  - Amyloid beta-Peptides/metabolism
MH  - tau Proteins/metabolism
MH  - *Cognitive Dysfunction
PMC - PMC10557994
OTO - NOTNLM
OT  - chronic inflammation
OT  - macrolide antibiotic
OT  - therapeutic effect
OT  - beta-amyloid
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/10/09 12:42
MHDA- 2023/11/01 12:42
PMCR- 2023/10/02
CRDT- 2023/10/09 06:11
PHST- 2023/07/07 00:00 [received]
PHST- 2023/09/25 00:00 [accepted]
PHST- 2023/11/01 12:42 [medline]
PHST- 2023/10/09 12:42 [pubmed]
PHST- 2023/10/09 06:11 [entrez]
PHST- 2023/10/02 00:00 [pmc-release]
AID - 429440 [pii]
AID - 10.2147/CIA.S429440 [doi]
PST - epublish
SO  - Clin Interv Aging. 2023 Oct 2;18:1629-1639. doi: 10.2147/CIA.S429440. eCollection 
      2023.